Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Amgen Inc. Stories

2013-02-07 08:27:17

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming the company's core strategy will continue to focus on innovation, discovery and development of breakthrough molecules to address significant unmet medical needs, and manufacturing of high-quality biologics....

2013-02-06 08:27:26

LONDON, February 6, 2013 /PRNewswire/ -- Pharma stocks performed fairly well lately. However, the main concern for all the major companies was related to the patent expiry of their blockbuster drugs. Amgen Inc. (NASDAQ: AMGN) is about to lose its patent exclusivity for its cancer drug Neupogen. However, the sector is also witnessing good merger and acquisition activities, where big players are acquiring smaller companies in order to make up the losses sustained through patent...

2013-01-30 08:21:38

NEW YORK, January 30, 2013 /PRNewswire/ -- Today, Traders Insight announced new research reports highlighting Marriott Vacations Worldwide Corp (NYSE: VAC), Copart, Inc. (Nasdaq: CPRT), Five Below, Inc. (Nasdaq: FIVE), City National Corp. (NYSE: CYN) and Amgen Inc. (Nasdaq: AMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Marriott Vacations Worldwide Corp Research...

2012-12-19 16:23:33

WASHINGTON, Dec. 19, 2012 /PRNewswire/ -- Sanford Heisler, LLP, a leading public interest law firm, today announced a $762 million global qui tam settlement with Amgen, Inc. and the United States Department of Justice. The settlement includes a $612 million civil settlement, a $14 million forfeiture and $136 million in criminal fines. Headquartered in Thousand Oaks, CA, Amgen is a leading human therapeutics company in the biotechnology industry. The whistleblower ("relator") who was...

2012-12-18 12:27:45

WASHINGTON, Dec. 18, 2012 /PRNewswire/ -- Sanford Heisler, LLP, a leading public interest law firm, today announced a $762 million global qui tam settlement with Amgen, Inc. and the United States Department of Justice. The settlement includes a $612 million civil settlement, a $14 million forfeiture and $136 million in criminal fines. Headquartered in Thousand Oaks, CA, Amgen is a leading human therapeutics company in the biotechnology industry. The whistleblower ("relator") who was...

2012-09-18 02:38:09

VANCOUVER, British Columbia, Sept. 18, 2012 /PRNewswire/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Microsoft (NASDAQ:MSFT), Exxon Mobil (NYSE:XOM), Starbucks (NASDAQ:SBUX), US Airways Group (NYSE:LCC), Amgen (NASDAQ:AMGN), and Boeing (NYSE:BA). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)...

2012-07-30 02:29:53

VANCOUVER, British Columbia, July 30, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: Expedia (NASDAQ:EXPE), Amarin (NASDAQ:AMRN), ENSCO (NYSE:ESV), Amgen (NASDAQ:AMGN), Wal-Mart (NYSE:WMT), and Nokia (NYSE:NOK). (Logo: http://photos.prnewswire.com/prnh/20120531/HK16417LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)...

2012-07-26 10:27:00

THOUSAND OAKS, Calif., July 26, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio. Amgen modified its agreement with Takeda to grant exclusive worldwide development rights for motesanib, recognizing income of $206 million in other revenues....

2012-04-24 10:25:38

THOUSAND OAKS, Calif., April 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first quarter of 2011. Adjusted earnings per share (EPS) were $1.61 for the first quarter of 2012, an increase of 20 percent compared to $1.34 for the first quarter of 2011. Adjusted net income increased 2 percent to $1,287 million in the first quarter of 2012 compared to $1,258 million in the...

2012-03-07 07:00:00

THOUSAND OAKS, Calif., March 7, 2012 /PRNewswire/ -- Amgen Inc. ("Amgen") (NASDAQ:AMGN) announced today the expiration of the subsequent offering period of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub," to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ:MITI) for $11.00 per share in cash. The subsequent offering period expired at 12:00 midnight, New York City time, at the end of Tuesday, March 6, 2012. The depositary for...